Dr. Mary Chamberlain-Tharp joined ARCH Venture Partners in July 2025. She comes with almost 30 years of industry experience in both R&D and Business Development, including her most recent role as Chief Business Officer at Neumora Therapeutics since 2021. Prior to that, Dr. Chamberlain-Tharp held multiple senior positions at AbbVie from 2014-2021 including Global Head of Academic Outreach and Global Head of External Innovation Scouting across all the various therapeutic and functional areas within the company as well as served as the Alliance Lead for multiple large partnerships. She was President and CEO at Z&D Biopharma Consulting PLLC in 2014. From 1997 to 2014, Dr. Chamberlain-Tharp held multiple senior positions including Head of Neuroscience and East Coast Operations/Global External R&D at Eli Lilly.
Dr. Chamberlain-Tharp holds a B.S. in Genetic Biology from Purdue University, an M.B.A. from Indiana University Bloomington and a Ph.D. in Clinical Psychiatric Epidemiology from Walden University. During her time at Eli Lilly, she received several awards including “Top 100” Innovator Award, the President’s Award and Woman in Lilly Discovery Award for her scientific and business development contributions to the company.